Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) traded up 5% during trading on Monday . The stock traded as high as $4.23 and last traded at $4.20. 1,358,506 shares were traded during trading, an increase of 37% from the average session volume of 988,997 shares. The stock had previously closed at $4.00.

Several equities research analysts have recently commented on the stock. BidaskClub downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. SunTrust Banks reiterated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Wednesday, November 29th. Piper Jaffray Companies set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 1st. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $6.25.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Nationwide Fund Advisors purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at $111,000. New York State Common Retirement Fund purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at $114,000. SG Americas Securities LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $144,000. State of Wisconsin Investment Board purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at $149,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Catalyst Pharmaceuticals by 1,861.3% in the second quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 59,896 shares in the last quarter. 34.83% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/13/catalyst-pharmaceuticals-cprx-trading-5-higher.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Stock Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related stocks with our FREE daily email newsletter.